Podcasts about serd

Good morning from Pharma and Biotech Daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.Genmab has acquired Merus, a rising star in the field of oncology, for $8 billion. The acquisition includes Merus' bispecific antibody, petosemtamab, which targets EGFR and LGR5 and has shown potential for head-and-neck cancer. In other news, GSK CEO Emma Walmsley is stepping down after nine years, with Chief Commercial Officer Luke Miels set to replace her next year. The FDA's decision to disclose complete response letters in real-time has raised questions about transparency and the agency's role. Additionally, Biogen has shuffled staff after ending work on AAV, while Heidelberg has cut 75% of its staff after missed royalty payments.The FDA's real-time disclosure of complete response letters benefits investors by providing greater visibility into regulatory decisions. In September, the FDA's actions included boosting Keytruda while rejecting two spinal muscular atrophy therapies due to manufacturing issues. A judge's ruling on the FDA's authority over laboratory-developed tests reflects the impact of a recent Supreme Court decision. Six FDA decisions to watch for in Q4 could have significant implications for the biopharma industry and patients. Recent developments include positive results for an immuneering asset in pancreatic cancer, FDA approval for Lilly's oral SERD for breast cancer, and positive outcomes for uniQure's Huntington's therapy. Additionally, the FDA is streamlining development of cell, gene, and regenerative therapies. Other news includes the revival of a dormant drug as a potential autism treatment, setbacks in obesity studies, and unexpected rejections for certain therapies. Upcoming webinars and job opportunities are also highlighted.Listeners are encouraged to provide feedback on topics they would like to see covered in future episodes.

Good morning from Pharma and Biotech daily: the podcast that gives you only what's important to hear in Pharma and Biotech world.President Trump has announced a 100% tariff deadline for pharmaceutical companies starting on October 1. However, companies that have already begun construction on manufacturing facilities in the U.S. are exempt from these tariffs. This move is part of the administration's efforts to lower drug prices and improve access to treatments for patients.In other news, Crinetics Pharmaceuticals has received FDA approval for their once-daily treatment for acromegaly, a rare pituitary condition. This approval marks a significant milestone for Crinetics and is expected to have a positive impact on patients' lives.Additionally, Lilly's oral SERD has been approved by the FDA for the treatment of breast cancer. This treatment has shown improved progression-free survival compared to standard therapy, offering new hope for patients battling this disease.The Trump administration is also preparing a proposed rule to further lower drug prices in the U.S., as part of an ongoing effort to align drug prices with other economically similar countries. These developments in the pharmaceutical industry are aimed at improving access to treatments and lowering costs for patients.

Sheinbaum informó que se solicitó integrar un nuevo grupo de expertos internacionales para el caso AyotzinapaOperativos contra venta de calzado asiático arrancarán en San Mateo AtencoEn América las mujeres indígenas tienen hasta tres veces más riesgo de morir durante el partoMás información en nuestro podcast

Elvitelre – a podcast, amelyben a hét legjobb HVG hetilapos és hvg360-as anyagaiból válogatunk. Csak indítsa el a háttérben és hallgassa meg szerzőink legjobb írásait! A héten: Putyin győzelmi kényszere Ukrajnában és váratlan kormányzati gesztus a magyar nők felé. Olvass még több prémium tartalmat a hvg360-on!

En la calle Serdán de Hermosillo se levanta un edificio común, pero sus paredes guardan uno de los secretos más oscuros de la ciudad. Allí existió un convento de monjas que, lejos de ser un refugio, se convirtió en un infierno para mujeres embarazadas y sus hijos. Restos emparedados, túneles ocultos y apariciones espectrales mantienen viva la leyenda. Quienes pasan de noche aseguran escuchar llantos de bebés y ver a mujeres embarazadas flotando en el aire… almas condenadas que jamás encontraron descanso.

En la Sierra Norte de Puebla, comunidades totonacas y más activistas ambientales se unieron para frenar la construcción de presas hidroeléctricas y minería a cielo abierto que amenazaban su territorio. A través de testimonios se evidencian los impactos ambientales, sociales y en la salud, especialmente de las mujeres, mostrándonos la importancia de la organización comunitaria para proteger el agua, la tierra y el futuro y la vida. Esta es una producción de Radio Itzahuatalix con el apoyo de Cultural Survival. Nuestros programas son gratuitos para escuchar, descargar y difundir. Música de introducción: - Burn Your Village to the Ground” by The Halluci Nation. Derechos de autor, propiedad de The Halluci Nation. Usada bajo su permiso. Música de fondo: - Bajo responsabilidad de Radio Itzahuatalix Voz: - Bajo dirección de Radio Itzahuatalix Guión, producción y edición: - Radio Itzahuatalix Imagen: - Radio Itzahuatalix

En la Sierra Norte de Puebla, comunidades totonacas y más activistas ambientales se unieron para frenar la construcción de presas hidroeléctricas y minería a cielo abierto que amenazaban su territorio. A través de testimonios se evidencian los impactos ambientales, sociales y en la salud, especialmente de las mujeres, mostrándonos la importancia de la organización comunitaria para proteger el agua, la tierra y el futuro y la vida. Esta es una producción de Radio Itzahuatalix con el apoyo de Cultural Survival. Nuestros programas son gratuitos para escuchar, descargar y difundir. Música de introducción: - Burn Your Village to the Ground” by The Halluci Nation. Derechos de autor, propiedad de The Halluci Nation. Usada bajo su permiso. Música de fondo: - Bajo responsabilidad de Radio Itzahuatalix Voz: - Bajo dirección de Radio Itzahuatalix Guión, producción y edición: - Radio Itzahuatalix Imagen: - Radio Itzahuatalix

Elvitelre – a podcast, amelyben a hét legjobb HVG hetilapos és hvg360-as anyagaiból válogatunk. Csak indítsa el a háttérben és hallgassa meg szerzőink legjobb írásait! A héten: kórházi klímakrízis és kuruzslásveszély. Iratkozz fel a hvg360-ra! hvg.hu/360/elofizetes Az e heti menü: 00:16 Átmeneti fellángolás volt a tavalyi válságkezelés, befagyott a kórházi klímaprogram (Galicza Dorina, Fetter Dóra) 08:29 Szépségipari balesetek (Serdült Viktória)

Hoy reconocemos que nuestras acciones del presente son las que nos guían a construir nuestro futuro.–A lo largo de estos 4 años de Despertando Podcast, hemos compartido episodios que les han ayudado muchísimo, y hoy queremos traerles de vuelta todas esas herramientas que han resonado con ustedes y cambiado sus mañanas ☀️.En este episodio hablamos de:Reconocer todo eso que has logrado hasta este momentoHacernos responsables de nuestro presente y nuestro futuroDarnos permiso de soñar y construir el camino que nos lleve a hacerlo posibleSi quieres conocer más de Despertando Podcast síguenos en nuestras redes sociales:

¿Qué perderías por una idea?La casa de los Hermanos Serdán en Puebla se convirtió en la primera trinchera real de la Revolución Mexicana dando el verdadero inicio el 18 de noviembre y no el 20 de noviembre como nos hicieron creer para olvidarlos. En este episodio nos acompañó nuestra amiga Ana Corcuera para platicar sobre cómo es que entre panfletos escondidos y rifles contrabandeados, Carmen, Aquiles, Natalia y Máximo desafiaron al régimen de Porfirio Díaz dos días antes del 20 de noviembre. Descubre cómo su comedor se volvió cuartel, por qué el disparo que mató a Aquiles sacudió al país y cómo el Estado olvidó a quienes iniciaron la lucha que cambió México.

Elvitelre – a podcast, amelyben a hét legjobb HVG hetilapos és hvg360-as anyagaiból válogatunk. Csak indítsa el a háttérben és hallgassa meg szerzőink legjobb írásait! A héten: Orbán nemzetközi befolyása, és a gyermekotthonok helyzete. Iratkozz fel a hvg360-ra! hvg.hu/360/elofizetes Az e heti menü: Serdült Viktória interjúja Hegedűs Dániellel Szabó Yvette: Pokoli gyermekotthonok Olvass még több prémium tartalmat a hvg360-on! Próbáld ki a hvg360-at most féláron

Dr. Allison Zibelli and Dr. Rebecca Shatsky discuss advances in breast cancer research that were presented at the 2025 ASCO Annual Meeting, including a potential new standard of care for HER2+ breast cancer, the future of ER+ breast cancer management, and innovations in triple negative breast cancer therapy. Transcript Dr. Allison Zibelli: Hello and welcome to the ASCO Daily News Podcast. I'm Dr. Allison Zibelli, your guest host of the podcast today. I'm an associate professor of medicine and a breast medical oncologist at the Sidney Kimmel Comprehensive Cancer Center at Jefferson Health. There was a substantial amount of exciting breast cancer data presented at the 2025 ASCO Annual Meeting, and I'm delighted to be joined by Dr. Rebecca Shatsky today to discuss some of these key advancements. Dr. Shatsky is an associate professor of medicine at UC San Diego and the head of breast medical oncology at the UC San Diego Health Moores Cancer Center, where she also serves as the director of the Breast Cancer Clinical Trials Program and the Inflammatory and Triple-Negative Breast Cancer Program.  Our full disclosures are available in the transcript of this episode. Dr. Shatsky, it's great to have you on the podcast today. Dr. Rebecca Shatsky: Thanks, Dr. Zibelli. It's wonderful to be here. Dr. Allison Zibelli: So, we're starting with DESTINY-Breast09, which was trastuzumab deruxtecan and pertuzumab versus our more standard regimen of taxane, trastuzumab pertuzumab for first-line treatment of metastatic HER2-positive breast cancer. Could you tell us a little bit about the study? Dr. Rebecca Shatsky: Yeah, absolutely. So, this was a long-awaited study. When T-DXd, or trastuzumab deruxtecan, really hit the market, a lot of these DESTINY-Breast trials were started around the same time. Now, this was a global, randomized, phase 3 study presented by Dr. Sara Tolaney from the Dana-Farber Cancer Institute of Harvard in Boston. It was assessing essentially T-DXd in the first-line setting for metastatic HER2-positive breast cancer in addition to pertuzumab. And that was randomized against our standard-of-care regimen, which was established over a decade ago by the CLEOPATRA trial, and we've all been using that internationally for at least the past 10 years. So, this was a large trial, and it was one-to-one-to-one of patients getting T-DXd plus pertuzumab, T-DXd alone, or THP, which mostly is used as docetaxel and trastuzumab and pertuzumab every three weeks for six cycles. And this was in over 1,000 patients; it was 1,159 patients with metastatic HER2-positive breast cancer. This was a very interesting trial. It was looking at the use of trastuzumab deruxtecan, but patients were started on this treatment for their first-line metastatic HER2-positive breast cancer with no end date to their T-DXd. So, it was, you know, you were started on T-DXd every 3 weeks until progression. Now, CLEOPATRA is a little bit different than that, though, as we know. So, CLEOPATRA has a taxane plus trastuzumab and pertuzumab. But generally, patients drop the taxane after about six to seven cycles because, as we know, you can't be really on a taxane indefinitely. You get pretty substantial neuropathy as well as cytopenias, other things that end up happening. And so, in general, that regimen has sort of a limited time course for its chemotherapy portion, and the patients maintained after the taxane is dropped on their trastuzumab and their pertuzumab, plus or minus endocrine therapy if the investigator so desires. And the primary endpoint of the trial was progression-free survival by blinded, independent central review (BICR) in the intent-to-treat population. And then it had its other endpoints as overall survival, investigator-assessed progression-free survival, objective response rates, and duration of response, and of course, safety. As far as the results of this trial, so, I think that most of us key opinion leaders in breast oncology were expecting that this was going to be a positive trial. And it surely was. I mean, this is a really, really active drug, especially in HER2-positive disease, of course. So, the DESTINY-Breast03 data really established that, that this is a very effective treatment in HER2-positive metastatic breast cancer. And this trial really, again, showed that. So, there were 383 patients that ended up on the trastuzumab plus deruxtecan plus pertuzumab arm, and 387 got THP, the CLEOPATRA regimen. What was really interesting also to note of this before I go on to the results was that 52% of patients on this trial had de novo metastatic disease. And that's pretty unusual for any kind of metastatic breast cancer trial. It kind of shows you, though, just how aggressive this disease is, that a lot of patients, they present with de novo metastatic disease. It's also reflecting the global nature of this trial where maybe the screening efforts are a little bit less than maybe in the United States, and more patients are presenting as later stage because to have a metastatic breast cancer trial in the United States with 52% de novo metastatic disease doesn't usually happen. But regardless, the disease characteristics were pretty well matched between the two groups. 54% of the patients were triple positive, or you could say hormone-positive because whether they were PR positive or ER positive and PR negative doesn't really matter in this disease. And so, the interim data cutoff was February of this year, of 2025. So, the follow-up so far has been about 29 months, so the data is still really immature, only 38% mature for progression-free survival interim analysis. But what we saw is that T-DXd plus pertuzumab, it really improved progression-free survival. It had a hazard ratio that was pretty phenomenal at 0.56 with a confidence interval that was pretty narrow of 0.44 to 0.71. So, very highly statistically significant data here. The progression-free survival was consistent across all subgroups. Overall survival, very much immature at this time, but of course, the trend is towards an overall survival benefit for the T-DXd group. The median durable response with T-DXd plus pertuzumab exceeded 3 years. Now, importantly, though, I want to stress this, is grade 3 or above treatment-emergent adverse events occurred in both subgroups pretty equally. But there were 2 deaths in the T-DXd group due to interstitial lung disease. And there was a 12.1% adjudicated drug-induced interstitial lung disease/pneumonitis event rate in the T-DXd group and only 1%, and it was grade 1-2, in the THP group. So, that's really the caveat of this therapy, is we know that a percentage of patients are going to get interstitial lung disease, and that some may have very serious adverse events from it. So, that's always something I keep in the back of my mind when I treat patients with T-DXd. And so, overall, the conclusions of the trial were pretty much a slam dunk. T-DXd plus pertuzumab, it had a highly statistically significant and clinically meaningful improvement in progression-free survival versus the CLEOPATRA regimen. And that was across all subgroups for first-line metastatic HER2-positive breast cancer here. And so, yeah, the data was pretty impressive. Just to go into the overall response rate, because that's always super important as well, you had 85.1% of patients having a confirmed overall RECIST response rate in the T-DXd plus pertuzumab group and a 78.6 in the CLEOPATRA group. The complete CR rate, complete response was 15.1% in the T-DXd group and 8.5 in the CLEOPATRA regimen. And it was really an effective regimen in this group, of course. Dr. Allison Zibelli: So, the investigators say at the end of their abstract that this is the new standard of care. Would you agree with that statement? Dr. Rebecca Shatsky: Yeah, that was a bold statement to make because I would say in the United States, not necessarily at the moment because the quality of life here, you have to think really hard about. Because one thing that's really important about the DESTINY-Breast09 data is that this was very much an international trial, and in many of the countries where patients enrolled on this, they were not able to access T-DXd off trial. And so, for them, this means T-DXd now or potentially never. And so, that is a really big difference whereas internationally, that may mean standard of care. However, in the US, patients have no issues accessing T-DXd in the second- or third-line settings. And right now, it's the standard of care in the second line in the United States, with all patients basically getting this second-line therapy except for some unique patients where they may be doing a PATINA trial regimen, which we saw at San Antonio Breast Cancer in 2024 of the triple-positive patients getting hormonal therapy plus palbociclib, which had a really great durable response. That was super impressive as well. Or there is the patient that the investigator can pick KADCYLA because the patient really wants to preserve their hair or maybe it's more indolent disease. But the quality of life on T-DXd indefinitely in the first-line setting is a big deal because, again, that CLEOPATRA regimen allows patients to drop their chemotherapy component about five to six months in. And with this, you're on a drug that feels very chemo-heavy indefinitely. And so, I think there's a lot more to investigate as far as what we're going to do with this data in the United States because it's a lot to commit a patient in the first-line metastatic setting. These de novo metastatic patients, some of them may be cured, honestly, on the HER2-targeting regimen. That's something we see these days. Dr. Allison Zibelli: So, very interesting trial. I'm sure we'll be talking about this for a long time.  So, let's move on to SERENA-6, which was, I thought, a very interesting trial. This trial took patients with ER positive, advanced breast cancer after six months on an AI (aromatase inhibitor) and a CDK4/6 inhibitor. They did ctDNA every two to three months, and when they saw an ESR1 mutation emerge, they changed half of the patients to camizestrant plus CDK4/6 and kept the other half on the AI plus CDK4/6. Can you talk about that trial a little bit, please? Dr. Rebecca Shatsky: Yeah, so this was a big trial at ASCO25. This was presented as a Plenary Session. So, this was camizestrant plus a CDK4/6 inhibitor, and it could have been any of the three, so palbo, ribo, or abemaciclib in the first-line metastatic hormone-positive population, and patients were on an AI with that. They were, interestingly, tested by ctDNA at baseline to see if they had an ESR1 mutation. So, that was an interesting feature of this trial. But patients had to have already been on their CDK4/6 inhibitor plus AI for at least 6 months to enroll. And then, as you mentioned, they got ctDNA testing every 2 to 3 months. This was also a phase 3, double-blind, international trial. And I do want to highlight again, international here, because that's important when we're considering some of this data in the U.S. because it influences some of the results. So, this was presented by Dr. Nick Turner of the Royal Marsden in the UK. So, just a little bit of background for our listeners on ESR1 mutations and why they're important. This is the most common, basically, acquired resistance mutation to patients being treated with aromatase inhibitors. We know that treatment with aromatase inhibitors can induce this. It makes a conformational change in the estrogen receptor that makes the estrogen receptor constitutively active, which allows the cell to signal despite the influence of the aromatase inhibitor to decrease the estrogen production so that the ligand binding doesn't matter as much as far as the cell signaling and transcription is concerned. And camizestrant, you know, as an oral SERD, just to explain that a little bit too; these are estrogen receptor degraders. The first-in-class of a selective estrogen receptor degrader to make it to market was fulvestrant. And that's really been our standard-of-care estrogen degrader for the past 25 years, almost 25 years. And so, a lot of us are just looking for some of these oral SERDs to replace that. But regardless, they do tend to work in the ESR1-mutated population. And we know that patients on aromatase inhibitors, the estimates of patients developing an ESR1 mutation, depending on which study you look at, somewhere between 30% to 50% overall, patients will develop this mutation with hormone-positive metastatic breast cancer. There is a small percentage of patients that have these at baseline without even treatment of an aromatase inhibitor. The estimates of that are somewhere between 0.5 and up to 5%, depending on the trial you look at and the population. But regardless, there is a chance someone on their CDK4/6 inhibitor plus AI at 6 months' time course could have had an ESR1 mutation at that time. But anyway, so they got this ctDNA every 2 to 3 months, and once they were found to develop an ESR1 mutation, the patients were then switched to the oral SERD. AstraZeneca's version of the oral SERD is camizestrant, 75 mg daily. And then their type of CDK4/6 inhibitor was maintained, so they didn't switch the brand of their CDK4/6 inhibitor, importantly. And that was looked at then for progression-free survival, but these were patients with measurable disease by RECIST version 1.1. And the data cut off here was November of 2024. This was a big trial, you know, and I think that that's influential here because this was 3,256 patients, and that's a lot of patients. So, they were all eligible. And then 315 patients ended up being randomized to switch to camizestrant upon presence of that ESR1 mutation. So, that was 157 patients. And then the other half, so they were randomized 1:1, they continued on their AI without switching to an oral SERD. That was 158 patients. They were matched pretty well. And so, their baseline characteristics, you know, the two subgroups was good. But this was highly statistically significant data. I'm not going to diminish that in any way. Your hazard ratio was 0.44. Highly statistically significant confidence intervals. And you had a median progression-free survival in those that switched to camizestrant of 16 months, and then the non-switchers was 9.2 months. So, the progression-free survival benefit there was also consistent across the subgroups. And so, you had at 12 months, the PFS rate was 60.7% for the non-treatment group and 33.4% in the treatment group. What's interesting, though, is we don't have overall survival data. This is really immature, only 12% mature as far as overall survival. And again, because this was an international trial and patients in other countries right now do not have the access to oral SERDs that the United States does, the crossover rate, they were not allowed to crossover, and so, a very few patients, when we look at progression-free survival 2 and ultimately overall survival, were able to access an oral SERD in the off-trial here and in the non-treatment group. And so, that's really important as far as we look at these results. Adverse events were pretty minimal. These are very safe drugs, camizestrant and all the other oral SERDs. They have some mild toxicities. Camizestrant is known for something weird, which is called photopsia, which is some flashing lights in the periphery of the eye, but it doesn't seem to have any serious clinical significance that we know of. It has a little bit of bradycardia, but it's otherwise really well tolerated. You know, I hate to say that because that's very subjective, right? I'm not the one taking the drug. But it doesn't have any serious adverse events that would cause discontinuation. And that's really what we saw in the trial. The discontinuation rates were really low. But overall, I mean, this was a positive trial. SERENA-6 showed that switching to camizestrant at the first sign of an ESR1 mutation on CDK4/6 inhibitor plus AI improved progression-free survival. That's all we can really say from it right now. Dr. Allison Zibelli: So, let's move on to ASCENT-04, which was a bit more straightforward. Sacituzumab govitecan plus pembrolizumab versus chemotherapy plus pembrolizumab in PD-L1-positive, triple-negative breast cancer. Could you talk about that study? Dr. Rebecca Shatsky: Yeah, so this was also presented by the lovely Sara Tolaney from Dana-Farber. And this study made me really excited. And maybe that's because I'm a triple-negative breast cancer person. I mean, not to say that I don't treat hundreds of patients with hormone- positive, but our unmet needs in triple negative are huge because this is a disease where you have got to throw your best available therapy at it as soon as you can to improve survival because survival is so poor in this disease. The average survival with metastatic triple-negative breast cancer in the United States is still 13-18 months, and that's terrible. And so, for full disclosure, I did have this trial open at my site. I was one of the site PIs. I'm not the global PI of the study, obviously. So, what this study was was for patients who had had at least a progression-free survival of 6 months after their curative intent therapy or de novo metastatic disease. They were PD-L1 positive as assessed by the Dako 22C3 assay of greater than or equal to a CPS score of 10. So, that's what the KEYNOTE-355 trial was based on as well. So, standard definition of PD-L1 positive in breast cancer here. And basically, these patients were randomized 1:1 to either their sacituzumab govitecan plus pembrolizumab, day 1 they got both therapies, and then day 8 just the saci, as is standard for sacituzumab. And then the other group got the KEYNOTE-355 regimen. So, that is pembrolizumab with – your options are carbogem there, paclitaxel or nab-paclitaxel. And it's up to investigator's decision which upon those they decided. They followed these patients for disease progression or unacceptable toxicity. It was really an impressive trial in my opinion because we know already that this didn't just improve progression-free survival, because survival is so poor in this disease, of course, we know that it improved overall survival. It's trending towards that very much, and I think that's going to be shown immediately. And then the objective response rates were better, which is key in this disease because in the first-line setting, you've got a lot of people who, especially your relapsed TNBC that don't respond to anything. And you lose a ton of patients even in the first-line setting in this disease. And so, this was 222 patients to chemotherapy and pembro and 221 to sacituzumab plus pembro. Median follow-up has only been 14 months, so it's still super early here. Hazard ratio so far of progression-free survival is 0.65, highly statistically significant, narrow confidence intervals. And so, the median duration of response here for the saci group was 16.5 months versus 9.2 months. So, you're getting a 7-month progression-free survival benefit here, which in triple negative is pretty fantastic. I mean, this reminds me of when we saw the ASCENT data originally come out for sacituzumab, and we were all just so happy that we had this tool now that doubled progression-free and overall survival and made such a difference in this really horrible disease where patients do poorly. So, OS is technically immature here, but it's really trending very heavily towards improvement in overall survival. Importantly, the treatment-related adverse events in this, I mean, we know sacituzumab causes neutropenia, people who are experienced with this drug know how to manage it at this point. There wasn't any really unexpected treatment-related adverse events. You get some people with sacituzumab who have diarrhea. It's usually pretty manageable with some Imodium. So, it was cytopenias predominantly in this disease in this population that were highlighted as far as adverse events. But I'm going to be honest, like I was surprised that this wasn't the plenary over the SERENA-6 data because this, in my mind, there we have a practice-changing trial. I will immediately be trying to use this in my PD-L1 population because, to be honest, as a triple-negative breast cancer clinical specialist, when I get a patient with metastatic triple-negative breast cancer who's PD-L1 positive, I think, "Oh, thank God," because we know that part of the disease just does better in general. But now I have something that really could give them a durable response for much longer than I ever thought possible when I started really heavily treating this disease. And so, this was immediately practice-changing for me. Dr. Allison Zibelli: I think that it's pretty clear that this is at least an option, if not the option, for this group of patients. Dr. Rebecca Shatsky: Yeah, the duration of responses here was – it's just really important because, I mean, I do think this will make people live longer. Dr. Allison Zibelli: So, moving on to the final study that we're going to discuss today, neoCARHP (LBA500), which was neoadjuvant taxane plus trastuzumab, pertuzumab, plus or minus carbo(platin) in HER2-positive early breast cancer. I think this is a study a lot of us have been waiting for. What was the design and the results of this trial? Dr. Rebecca Shatsky: I was really excited about this as well because I'm one of those people that was waiting for this. This is a Chinese trial, so that is something to take note of. It wasn't an international trial, but it was a de-escalation trial which had become really popular in HER2-positive therapy because we know that we're overtreating HER2-positive breast cancer in a lot of patients. A lot of patients we're throwing the kitchen sink at it when maybe that is not necessary, and we can really de-escalate and try to personalize therapy a little bit better because these patients tend to do well. So, the standard of care, of course, in HER2-positive curative intent breast cancer with tumors that are greater than 2 cm is to give them the TCHP regimen, which is docetaxel, carboplatin, trastuzumab, and pertuzumab. And that was sort of established by several trials in the NeoSphere trial, and now it's been repeated in a lot of different studies as well. And so, that's really the standard of care that most people in the United States use for HER2-positive curative intent breast cancer. This was a trial to de-escalate the carboplatin, which I was super excited about because many of us who treat this disease a lot think carbo is the least important part of the therapy you're giving there. We don't really know that it's necessary. We've just been doing it for a long time, and we know that it adds a significant amount of toxicity. It causes thrombocytopenia, it causes severe nausea, really bad cytopenias that can be difficult in the last few cycles of this to manage. So, this trial was created. It randomized patients one to one with stage 2 and 3 HER2-positive breast cancer to either get THP, a taxane, pertuzumab, trastuzumab, similar to the what we do in first-line metastatic HER2-positive versus the whole TCHP with a carboplatin AUC of 6, which is what's pretty standard. And it was a non-inferiority trial, so important there. It wasn't to establish superiority of this regimen, which none of us, I think, were looking for it to. And it was a modified intent-to-treat population. And so, all patients got at least one cycle of this to be assessed as a standard for an intent-to-treat trial. And so, they assumed a pCR rate of about 62.8% for both groups. And, of course, it included both HER2-positive triple positives and ER negatives, which are, you know, a bit different diseases, to be honest, but we all kind of categorize them and treat them the same. And so, this trial was powered appropriately to detect a non-inferiority difference. And so, we had about 380 patients treated on both arms, and there was an absolute difference of only 1.8% of those treated with carbo versus those without. Which was fantastic because you really realized that de-escalation here may be something we can really do. And so, the patients who got, of course, the taxane regimen had fewer adverse events. They had way fewer grade 3 and 4 adverse events than the THP group. No treatment-associated deaths occur, which is pretty standard for- this is a pretty safe regimen, but it causes a lot of hospitalizations due to diarrhea, due to cytopenias, and neutropenic fever, of course. And so, I thought that this was something that I could potentially enact, you know, and be practice-changing. It's hard to say that when it's a trial that was only done in China, so it's not necessarily the United States population always. But I think for patients moving forward, especially those with, say, a 2.5 cm tumor, you know, node negative, those, I'd feel pretty comfortable not giving them the carboplatin here. Notes that I want to make about this population is that the majority were stage 2 and not stage 3. They weren't necessarily your inflammatory HER2-positive breast cancer patients. And that the taxane that was utilized in the trial is a little different than what we use in the United States. The patients were allowed to get nab-paclitaxel, which we don't have FDA approval for in the first-line curative intent setting for HER2-positive breast cancer in the United States. So, a lot of them got abraxane, and then they also got paclitaxel. We tend to use docetaxel every 3 weeks in the United States. So, just to point out that difference. We don't really know if that's important or not, but it's just a little bit different to the population we standardly treat. Dr. Allison Zibelli: So, are there patients that you would still give TCHP to? Dr. Rebecca Shatsky: Yeah, great question. I've been asked that a lot in the past like week since ASCO. I'd say in my inflammatory breast cancer patients, that's a group I do tend to sometimes throw the kitchen sink at. Now, I don't actually use AC in those because I know that that was the concern, but I think the TRAIN-2 trial really showed us you don't need to use Adriamycin in HER2-positive disease unless it's like refractory. So, I don't know that I would throw this on my stage 3C or inflammatory breast cancer patients yet because the majority of this were not stage 3. So, in your really highly lymph node positive patients, I'm a little bit hesitant to de-escalate them from the start. This is more of a like, if there's serious toxicity concerns, dropping carbo is absolutely fine here. Dr. Allison Zibelli: All right, great.  Thank you, Dr. Shatsky, for sharing your valuable insights with us on the ASCO Daily News Podcast today. Dr. Rebecca Shatsky: Thanks so much, Dr. Zibelli and ASCO Daily News. I really want to thank you for inviting me to talk about this today. It was really fun, and I hope you find my opinions on some of this valuable. And so, I just want to thank everybody and my listeners as well. Dr. Allison Zibelli: And thank you to our listeners for joining us today. You'll find the links to all the abstracts discussed today in the transcript of this episode. Finally, if you like this podcast and you learn things from it, please take a moment to rate, review, and describe because it helps other people find us wherever you get your podcasts. Thank you again. Disclaimer: The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement. More on today's speakers Dr. Allison Zibelli Dr. Rebecca Shatsky @Dr_RShatsky Follow ASCO on social media:  @ASCO on Twitter  @ASCO on Bluesky  ASCO on Facebook  ASCO on LinkedIn   Disclosures: Dr. Allison Zibelli: No relationships to disclose Dr. Rebecca Shatsky: Consulting or Advisory Role: Stemline, Astra Zeneca, Endeavor BioMedicines, Lilly, Novartis, TEMPUS, Guardant Health, Daiichi Sankyo/Astra Zeneca, Pfizer Research Funding (Inst.): OBI Pharma, Astra Zeneca, Greenwich LifeSciences, Briacell, Gilead, OnKure, QuantumLeap Health, Stemline Therapeutics, Regor Therapeutics, Greenwich LifeSciences, Alterome Therapeutics  

You've probably heard that authoritarianism is on the rise across the globe. Increasingly, countries are adopting policies that undermine democracy, reduce accountability, and erode civil liberties and human rights. But why is authoritarianism on the rise, and how do authoritarian leaders come to power? Lauded by Donald Trump and condemned by rights-defenders, Hungary's Prime Minister Viktor Orban provides a useful case study for those hoping to better understand the authoritarians' playbook. This week, host Ngofeen Mputubwele speaks to a Hungarian journalist and civil liberties strategist to map Orban's journey to autocracy, and how his lurch towards authoritarianism has decimated civil liberties and allowed him to exert a stranglehold on Hungarian politics for more than 15 years. Stefania Kopronczay: Former director of the Hungarian Civil Liberties Union; visiting scholar at Columbia University Viktória Serdült: Journalist at HVG.HU

Llegamos al noveno paso en este camino llamado Historia y Teología de la Reforma Radical. En este episodio, el maestro Fabián Cabezas, especialmente aborda el testimonio de las iglesias anabautistas como discípulas del Señor en medio de un contexto de persecución y de sismos sociales. Un Momento de Anabautismo se ha ido al podcast Textos IBA y traemos esta bella serie que nos cuenta sobre las bases históricas, comunales y teológicas de las iglesias Anabautistas.

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Evaluating first-line treatment of metastatic ER-positive, HER2-positive breast cancer: heredERA Breast Cancer study (0:00) Kuemmel S et al. heredERA Breast Cancer: A phase III, randomized, open-label study evaluating the efficacy and safety of giredestrant plus the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection in patients with previously untreated HER2-positive, estrogen receptor-positive locally advanced or metastatic breast cancer. BMC Cancer 2024;24(1):641. Abstract  Treatment outcomes with CDK4/6 inhibitors and with elacestrant in real-world studies (4:13) Lloyd MR et al. CDK4/6 inhibitor efficacy in ESR1-mutant metastatic breast cancer. NEJM Evid 2024;3(5). Abstract  Lloyd M et al. Impact of prior treatment, ESR1 mutational (ESR1m) landscape, and co-occurring PI3K pathway status on real-world (RW) elacestrant outcomes in patients (pts) with hormone receptor-positive (HR+)/HER2-negative advanced breast cancer (aBC). San Antonio Breast Cancer Symposium 2024;Abstract PS7-05.  Evaluating the CNS activity of imlunestrant, an oral selective estrogen receptor degrader (SERD) (8:06) VandeKopple M et al. Preclinical characterization of imlunestrant, an oral brain-penetrant selective estrogen receptor degrader with activity in a brain metastasis (BM) model. ESMO Breast 2023;Abstract 41P.  Selective review of trials of oral SERDs in the adjuvant setting (11:27) A study of imlunestrant versus standard endocrine therapy in participants with early breast cancer (EMBER-4). NCT05514054 CME information and select publications

Featuring an interview with Dr Rinath M Jesselsohn, including the following topics: Imlunestrant with or without abemaciclib in advanced breast cancer: Results of the Phase III EMBER-3 trial (0:00) Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2025;392(12):1189-202. Abstract  Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the Phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1 and PTEN in HR-positive, HER2-negative metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice (7:00) Bhave MA et al. Comprehensive genomic profiling of ESR1, PIK3CA, AKT1, and PTEN in HR(+)HER2(-) metastatic breast cancer: Prevalence along treatment course and predictive value for endocrine therapy resistance in real-world practice. Breast Cancer Res Treat 2024;207(3):599-609. Abstract Camizestrant, a next-generation oral selective estrogen receptor degrader (SERD), versus fulvestrant for postmenopausal women with estrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomized, Phase II trial (10:25) Oliveira M et al. Camizestrant, a next-generation oral SERD, versus fulvestrant in post-menopausal women with oestrogen receptor-positive, HER2-negative advanced breast cancer (SERENA-2): A multi-dose, open-label, randomised, phase 2 trial. Lancet Oncol 2024;25(11):1424-39. Abstract Latest on SERDs: An education session at San Antonio Breast Cancer Symposium 2024 (13:57) Jeselsohn RM. Latest on selective estrogen receptor degraders (SERDs). San Antonio Breast Cancer Symposium 2024;Education Session 5. CME information and select publications

Elvitelre – a podcast, amelyben a hét legjobb HVG hetilapos és hvg360-as anyagaiból válogatunk. Csak indítsa el a háttérben és hallgassa meg szerzőink legjobb írásait! A héten: üldözési törvényjavaslat Magyarországon. Iratkozz fel a hvg360-ra! hvg.hu/360/elofizetes A mai menü: 00:00 Intro 00:16 Elmagyarázzuk, mivel jár és mi a legveszélyesebb a Fidesz új üldözési törvényében – kérdések, válaszok és kétségek (Serdült Viktória, Lengyel Tibor)

Jesús utiliza a menudo comparaciones con mucha simbología para enseñar. En este episodio intentamos profundizar en una de las muchas comparaciones que hace el Señor de sí mismo y que podéis leer en el capítulo 10 del Evangelio de Juan, Jesús como El Buen Pastor. Comentamos también el camino de la nada, de San Juan de la Cruz.

In Italia, la dipendenza da sostanze è un fenomeno che coinvolge sempre più donne e che spesso resta sommerso. Secondo le statistiche, una persona su tre che consuma sostanze è donna, ma solo il 14% delle persone in carico ai Serd - servizi per le dipendenze - è di genere femminile. Violenza di genere, vulnerabilità economiche, contesto famigliare sono tra le cause della dipendenza al femminile. Qual è, dunque, il modo corretto di dare supporto a questo donne? Come sostenerle? Ne parliamo con le responsabili della cooperativa Dianova e con le donne del centro di Garbagnate milanese.

Il fenomeno della dipendenza, intesa come ricerca esagerata e patologica del piacere tramite sostanze o comportamenti, ha assunto ormai i connotati di un'autentica emergenza. Una piaga che, nel caso dei giovanissimi, è fonte di allarme. Diventa quindi fondamentale dare risalto e visibilità a quelle realtà impegnate nel contrasto a tale tendenza. Una di queste, nel Vicentino, è il Servizio Dipendenze (Serd) dell'Ulss 7 Pedemontana. Giovanni Greco, direttore del Servizio, ne ha parlato con Mariagrazia Bonollo e Gianni Manuel ai microfoni di Radio Eco Vicentino.

Featuring an interview with Dr Komal Jhaveri, including the following topics: Imlunestrant, an oral selective estrogen receptor degrader (SERD), with and without abemaciclib for ER-positive, HER2-negative advanced or metastatic breast cancer (0:00) Jhaveri KL et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), as monotherapy & combined with abemaciclib, for patients with ER+, HER2- advanced breast cancer (ABC), pretreated with endocrine therapy (ET): Results of the phase 3 EMBER-3 trial. San Antonio Breast Cancer Symposium 2024;Abstract GS1-01. Jhaveri KL et al. Imlunestrant with or without abemaciclib in advanced breast cancer. N Engl J Med 2024;[Online ahead of print]. Abstract Rugo HS et al. Elacestrant abemaciclib (abema) combination in patients (pts) with estrogen receptor-positive (ER+), HER2-negative (HER2-) advanced or metastatic breast cancer (mBC). San Antonio Breast Cancer Symposium 2024; Abstract PS7-07. Elacestrant for ER-positive, HER2-negative metastatic breast cancer with ESR1-mutated tumors: Subgroup analyses from the Phase III EMERALD trial by duration of prior endocrine therapy with a CDK4/6 inhibitor and in clinical subgroups (7:40) Bardia A et al. Elacestrant in ER+, HER2- MBC with ESR1-mutated tumors: Subgroup analyses from the phase III EMERALD trial by prior duration of endocrine therapy plus CDK4/6 inhibitor and in clinical subgroups. Clin Cancer Res 2024;30(19):4299-309. Abstract Pharmacokinetics and safety of imlunestrant in patients with hepatic impairment (11:25) Wang XA et al. Evaluation of pharmacokinetics and safety of imlunestrant in participants with hepatic impairment. San Antonio Breast Cancer Symposium 2024;Abstract P4-10-07. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer (13:15) Lloyd MR et al. Precision therapeutics and emerging strategies for HR-positive metastatic breast cancer. Nat Rev Clin Oncol 2024;21(10):743-61. Abstract CME information and select publications

Featuring an interview with Dr Seth Wander, including the following topics: Therapy selection after CDK4/6 inhibitor failure: A review of current and investigational treatment for HR-positive, HER2-negative breast cancer Astore S et al. A therapeutic algorithm guiding subsequent therapy selection after CDK4/6 inhibitors' failure: A review of current and investigational treatment for HR+/Her2- breast cancer. Crit Rev Oncol Hematol 2024;204:104535. Abstract (0:00) A preoperative window-of-opportunity study of the oral SERD imlunestrant for newly diagnosed ER-positive, HER2-negative localized breast cancer Neven P et al. A preoperative window-of-opportunity study of oral SERD, imlunestrant, in newly diagnosed ER-positive, HER2-negative early breast cancer: Results from the EMBER-2 Study. Clin Cancer Res 2024;30(23):5304-13. Abstract (3:30) An assessment of an exosome-based ESR1-monitoring RT-qPCR kit that detects acquired resistance variants in liquid biopsy samples Statt S et al. An exosome-based ESR1 monitoring RT-qPCR kit that rapidly and accurately detects acquired resistance variants at ≤ 0.1% frequency in liquid biopsy samples. ESMO 2024;Abstract 420P. (7:08) CME information and select publications

Catch up on new data from San Antonio on innovative treatments and patient-centered management strategies for estrogen receptor (ER)-positive metastatic breast cancer (MBC). Credit available for this activity expires: 01/13/26 Earn Credit / Learning Objectives & Disclosures: https://www.medscape.org/viewarticle/1002163?ecd=bdc_podcast_libsyn_mscpedu

Somos dóciles al Espíritu Santo haciendo nuestro cuerpo grato a Él, al pedirle que nos afiance en los misterios de la fe y al orar junto a María, los santos, el ángel de la guarda y en comunidad.

* El debate sobre cómo se cocina el fentanilo * Año empieza con impuesto a comercio electrónico * Y no puede ser Día de Reyes sin la rosca del Costco

In this JCO Article Insights episode, Giselle de Souza Carvalho provides a summary on  "Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies" by Bhardwarj, et al and "US Food and Drug Administration Approval Summary: Capivasertib With Fulvestrant for Hormone Receptor–Positive, Human Epidermal Growth Factor Receptor 2–Negative Locally Advanced or Metastatic Breast Cancer With PIK3CA/AKT1/PTEN Alterations" by Dilawari et al published in the Journal of Clinical Oncology.  TRANSCRIPT Giselle Carvalho: Hello and welcome to JCO Article Insights episode for the December issue of the Journal of Clinical Oncology. I'm your host Giselle Carvalho, Medical Oncologist in Brazil focusing on breast cancer and melanoma skin cancers and one of the ASCO Editorial Fellows at JCO this year. Today, I will be discussing two articles. The first one is “Navigating Treatment Pathways in Metastatic Hormone Receptor–Positive, HER2-Negative Breast Cancer: Optimizing Second-Line Endocrine and Targeted Therapies,” and the second one is the “US FDA Approval Summary on Capivasertib with Fulvestrant  for HR-positive HER2-negative Locally Advanced or Metastatic Breast Cancer with PIK3CA/AKT1/PTEN Alteration.”  As we know, 65% to 70% of all breast cancers are HR-positive HER2-negative and this is also the most common subtype of metastatic breast cancer. The current standard of care for frontline therapy of patients with luminal metastatic disease is a CDK4/6 inhibitor in combination with endocrine therapy. However, as new endocrine and targeted therapies gain approval, choosing the best systemic therapy upon disease progression after frontline therapy is a topic of ongoing debate. Nearly 40 to 50% of HR-positive breast cancers have actionable genomic alterations and molecular testing should be a routine recommendation for patients with metastatic HR-positive HER2-negative disease. This can be performed repeating tissue biopsy at the time of progression or from archival tissue. Treatment options after progression on CDK4/6 inhibitors include alpelisib in combination with fulvestrant in patients with PIK3CA mutant tumors as seen in the SOLAR-1 trial, or capivasertib with fulvestrant in patients with a tumor mutation in (PI3K)–AKT–PTEN pathway as seen in the CAPItello-291 study, which will be discussed further.  In approximately 30% of patients, progression on frontline endocrine plus CDK4/6 inhibitor treatment is caused by endocrine resistance, frequently involving activating mutations in ESR1. For those tumors, elacestrant, an oral SERD is an option as demonstrated in the EMERALD trial. For patients with a BRCA mutation, PARP inhibitors represent another option. If no mutations are detected, everolimus, an mTOR inhibitor, can be used based on the BOLERO-2 results. The phase 2 MAINTAIN and PACE trials, along with the phase 3 postMONARCH trial support changing the endocrine therapy backbone with or without switching the CDK4/6 inhibitor. In less resourced areas, fulvestrant monotherapy is still an option to delay cytotoxic chemotherapy, though its efficacy is limited when used as a single agent. Finally, after progression on at least one line of chemotherapy, antibody drug conjugates including sacituzumab govitecan or trastuzumab deruxtecan may be an option.  Now focusing on the PI3K AKT PTEN signaling pathway, activating mutations in PIK3CA and AKT1 and inactivating alterations in PTEN occur in approximately half of luminal breast cancers. In June 2023, the CAPItello-291 trial was published and treatment with fulvestrant plus capivasertib, a PTEN AKT inhibitor, demonstrated a 3.6 month PFS benefit compared to fulvestrant alone, regardless of the presence of AKT pathway alterations. However, for those with tumors without AKT pathway alteration, an exploratory analysis showed that although there was a numerical improvement in PFS, it did not meet statistical significance, indicating that the biomarker positive population primarily drove the positive results noted in the overall population. Therefore, capivasertib plus fulvestrant was approved by the US FDA in November 2023 exclusively for patients with PI3K/AKT1/PTEN tumor alterations after progression on an aromatized inhibitor with or without a CDK4/6 inhibitor. The approved schedule of capivasertib is slightly different from that of other agents used in breast cancer. It is 400 milligrams taken orally twice a day for four days per week every week in a 28-day cycle in combination with fulvestrant. Diarrhea, rash and hyperglycemia were the most commonly reported grade three or four adverse events in the interventional group. I would like to highlight that even though the CAPItello trial excluded patients with glycosylated hemoglobin levels higher than 8% or those diagnosed with diabetes who required insulin, hyperglycemia occurred in 19% of biomarker positive patients treated with capivasertib, with nearly 2% of this population experiencing grade 3 or 4 hyperglycemia and some patients experiencing life threatening outcomes such as diabetic ketoacidosis.  By way of comparison, hyperglycemia of any grade was three times higher with alpelisib therapy in the SOLAR-1 trial, occurring in 64% of the patients and grade three or higher hyperglycemia was seen in 37% of the patients. Diarrhea was the most common treatment related adverse event experienced by 77% of the biomarker positive population. Prompt use of the antidiarrheal drugs when needed, such as loperamide must be encouraged as untreated diarrhea can lead to dehydration and renal injury. Cutaneous rash occurred in 56% of the biomarker positive population in the interventional group and 15% experienced a grade 3 or 4 rash. Nearly half of the patients with cutaneous adverse reactions required treatment and this was the leading reason for dose reduction of capivasertib.  In the biomarker positive population, the improvement in medium PFS were 4.3 months by investigator assessment. Overall survival data from the CAPItello-291 trial is still immature, but quality of life data was recently published in September this year and was assessed by the 30 item QLQ C30 questionnaire and the QLQ BR23, the breast module. According to Oliveira et al, global health status and quality of life were maintained for a longer period with capivasertib fulvestrant than with placebo fulvestrant except for symptoms of diarrhea which were significantly worse in the capivasertib group. The median time of deterioration of global health status and quality of life was twice as long in the capivasertib group being almost 25 months versus 12 months in the placebo fulvestrant group. These data reinforced the use of capivasertib in combination with fulvestrant for the treatment of HR-positive HER2-negative advanced breast cancer patients with PIK3CA/AKT1/PTEN tumor alterations who have progressed after an aromatase inhibitor-based therapy with or without a CDK4/6 inhibitor.  Thank you for listening to JCO Article Insights. This is Giselle Carvalho. Don't forget to give us a rating or review and be sure to subscribe so you never miss an episode. You can find all ASCO shows at asco.org/podcasts. See you next time.   The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions.  Guests on this podcast express their own opinions, experience and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity or therapy should not be construed as an ASCO endorsement.  

Featuring an interview with Dr Seth Wander, including the following topics: Design of SERENA-6, a Phase III switching trial of camizestrant for ESR1-mutant breast cancer during first-line treatment Turner N et al. Design of SERENA-6, a phase III switching trial of camizestrant in ESR1-mutant breast cancer during first-line treatment. Future Oncol 2023;19(8):559-73. Abstract (0:00) EMERALD trial analysis of patient-reported outcomes with oral elacestrant compared to standard of care endocrine therapy for ER-positive, HER2-negative advanced or metastatic breast cancer Cortes J et al. EMERALD trial analysis of patient-reported outcomes (PROs) in patients with ER+/HER2− advanced or metastatic breast cancer (mBC) comparing oral elacestrant vs standard of care (SoC) endocrine therapy. ESMO Breast 2023;Abstract 188O. (5:50) Imlunestrant, an oral selective estrogen receptor degrader, in combination with HER2-directed therapy, with or without abemaciclib, for ER-positive, HER2-positive advanced breast cancer Bhave MA et al. Imlunestrant, an oral selective estrogen receptor degrader (SERD), in combination with human epidermal growth factor receptor 2 (HER2) directed therapy, with or without abemaciclib, in estrogen receptor (ER) positive, HER2 positive advanced breast cancer (aBC): EMBER phase 1a/1b study. ASCO 2024;Abstract 1027. (9:43) CME information and select publications

Ez az Elvitelre, a hvg.hu hétzáró podcastja. A 92. adásban: Spermadonorok és a Magyar Kereskedelmi és Iparkamara. Iratkozz fel a hvg360-ra! hvg.hu/360/elofizetes Az e heti menü: 00:00 Intro 00:32 Magyarországon is akkorát zuhant a férfiak nemzőképessége, hogy már alig akad spermadonor (Serdült Viktória) 06:44 Parragh megbuktatása is Orbánnak szóló üzenet lehet a gazdaságpolitika bírálóitól (Szabó Yvette)

En la sesión de hoy, reflexionamos sobre la importancia de reconocer nuestro valor esencial, ese valor que no depende de lo que hacemos o de cómo nos perciben los demás, sino que existe simplemente por ser quienes somos. Acompáñame en un viaje de autovaloración y aceptación, donde nos liberamos de la necesidad de validación externa y abrazamos nuestra esencia con amor y autenticidad.¿Te gustó está sesión? Compártela con un ser querido, ayúdanos a expandir la energía de la gratitud para que todes disfrutemos los beneficios de los increíbles beneficios de esta práctica.Descarga tu Diario de Gratitud: www.mardelcerro.com/gratitudConecta con nosotres más allá del Podcast nos encuentras en:Instagram: www.instagram.com/meditaconmigocastInstagram: www.instagram.com/mardelcerroCorreo: mar@mardelcerro.com Gracias siempre por ser parte de este proyecto.AGRADECIDA es un podcast de Medita Conmigo CastProducción, guión y voz: Marimar del Cerro Coordinación general: Fernanda VargasEdición, diseño de sonido y música original: Silver Media StudioImágen y redes sociales: Zayuri Vargas, Valery Martinez, Mariana Torres y Daniela Calderón.¡Gracias equipo por hacer esto posible! Hosted on Acast. See acast.com/privacy for more information.

Orbán Viktort szerdán összeszidták. Adósa kritikusainak ő sem maradt, de magasról kapott ki, hiszen Manfred Weber mellett Ursula von der Leyen is perceken keresztül őt ostorozta. A miniszterelnök és kormánya strasbourgi tudósítónk szerint átlépett egy olyan vörös vonalat, amit már az EU nem hagyhatott szó nélkül, ezért hányták a szemére órákon keresztül a kínai és az orosz kapcsolatokat, a korrupciót, sőt, még a kivándorlást is. Mindez pedig meglephette a miniszterelnököt, akinek válaszai egy ponton szokatlan személyeskedésbe csúsztak át. A szerdai nap másik nagy attrakciójának előzetesen Magyar Pétert hittük – Magyar azonban öt percében egyszerre hadart el mindent, amit a kormány hibájának vélt, de nem mondott szinte semmit arról, hogy mit akar ezzel a helyzettel kezdeni. Az Európai Parlament szerdai plenáris üléséről, a magyar uniós elnökségről, a Draghi-jelentésről, Magyar Péterről, valamint Orbán vélt, vagy valós elszigetelődéséről beszélgetett a HVG-t Strasbourgból tudósító Serdült Viktóriával, valamint Arató Lászlóval, az Eurologus újságírójával Kacskovics Mihály Béla. Iratkozz fel a Fülke csatornájára! Spotify: tiny.cc/FulkeSpotify Apple Podcasts: tiny.cc/FulkeApple Hallgasd meg a HVG többi podcastját: Spotify: tiny.cc/HVGpodcastokSpotify Apple Podcasts: tiny.cc/HVGpodcastokApple SoundCloud: tiny.cc/HVGpodcastokSC 00:00 Mit tartalmaz a Draghi-jelentés? 01:32 Hogyan viszonyul a jelentéshez Magyarország? 05:29 Hogy telt eddig Magyarország uniós elnöksége? 07:46 Mitől függ, hogy mennyire sikeres egy uniós elnökség? 09:33 Milyen szerepe lehet az uniós pozíciók kiosztásában soros elnökként Magyarországnak? 10:25 Mi a „Schengen summit”, amit Orbán Viktor a keddi sajtótájékoztatóján jelentett be? 13:23 Miért érezte szükségét Ursula Von der Leyen annak, hogy párhuzamot vonjon az '56-os forradalom és az ukrán védekezés között? 17:32 Milyen újabb eszközöket vethet be az EP a jogállamiság védelmére? 18:57 Mivel kritizálta Orbán Viktort Manfred Weber, és hogyan reagált erre a magyar miniszterelnök? 21:16 Hogyan csaptak össze a Tisza-párt képviselői Orbán Viktorral? 24:05 Mivel kritizálta Orbánt Valéria Hayer, a Renew frakció vezetője? 27:56 Miért nem reagált a Néppárt és Magyar Péter Ilaria Salis megszólalására? 30:38 Mennyire elszigetelt jelenleg az EP-ben Orbán Viktor?

Az e heti podcastban: a Fidesz legújabb sztárigazolása az amerikai republikánusok jobbszéléről, áldatlan állapotok a bíróságokon, és mindenki kedvence: a ledolgozós szombati munkanap. Iratkozz fel a hvg360-ra, az első hónapban csupán 360 forintért! hvg.hu/360/elofizetes Az e heti menü: 00:32 Egy a jelszó: a harc (Martini Noémi, Szentirmai Áron) 08:00 „Éhen halok, ha nem mondok fel a bíróságon” (Serdült Viktória) 16:28 Megint melózni kellett a négynapos ünnepért – de van bármi értelme egy ledolgozós szombati munkanapnak? (Sztojcsev Iván)

„A maga természetességében mutatja meg az erdő, hogy mit jelent a természeti törvények áthágása” – mondta az 1992-es interjúban Balogh János zoológus, ökológus. Trópusi őserdők talajfaunáját vizsgálva az elsők között figyelmeztetett az emberiség fennmaradását veszélyeztető káros folyamatokra.

Békemisszióval, védelmi hozzájárulással és a háborús propaganda elleni leszámolással (tetszőleges számú idézőjel kihelyezése indokolt) ágyazott meg a kormány nyáron egy sűrű ősznek: készül az újabb sajtóellenes leszámolás és folytatódik a gazdaság összefoltozása, de sem a békenarratíva, sem a nagy tusványosi víziók, sem a Patrióták összeboronálása nem változtat a képen, hogy a kormány nehezebb hónapok elé néz a politikai élet újraéledésével, mint bármikor az elmúlt 14 év során. Hogyan fektette le az alapokat Lánczi Tamás, milyen „háborúspropaganda-ellenes” törvényt találhat ki az Igazságügyi Minisztérium és milyen célt szolgálna, ha tényleg elfogadnák? Tényleg lesznek-e határon túli választókerületek és valójában hol kell megerősödnie a Tiszának 2026-ra? Mit jelentenek a kötelezettségszegési- és túlzottdeficit-eljárások? Hogyan csapódhatnak le a megszorítások és készül-e jövő évi pénzosztásra a kormány? Miért nem indul be igazán az európai politikai élet 2024 végéig és mire számíthatunk az új önkormányzatok felállásával? Közéleti podcastunkban erről beszélgettek a HVG újságírói, Serdült Viktória, Kacskovics Mihály Béla és Kovács Gábor Nagy Iván Lászlóval – akinek ez volt az utolsó adása a Fülke házigazdájaként, így az adásból az is kiderül, hogyan folytatódik a műsor a jövőben. Iratkozz fel a Fülke csatornájára!   Spotify: https://tiny.cc/FulkeSpotify  Apple Podcasts: https://tiny.cc/FulkeApple  Hallgasd meg a HVG többi podcastját:   Spotify: https://tiny.cc/HVGpodcastokSpotify  Apple Podcasts: https://tiny.cc/HVGpodcastokApple  SoundCloud: https://tiny.cc/HVGpodcastokSC 00:00 Intro 02:18 Hogyan alapozta meg Lánczi Tamás a háborúspropaganda-törvényt? 13:54 Hogy csúszhatna át az EU-n egy ilyen törvény? 18:55 Mire elegendőek a megszorítások, és mit fogunk érezni belőle? 23:22 Hogyan érintheti a magyar gazdaságot Donald Trump visszatérése? 26:06 Miért nem költenek a magyarok? 28:07 Lesz-e pénzeső 2025 végén? 30:13 Lehetnek-e egyéni választókerületek a határon túl? 36:10 Mekkora siker valójában a Patrióták összeállása? 39:56 Mi várható még a soros elnökség alatt? 41:47 Hol tart most a Tisza az EU-ban? 47:51 Mi történt eddig, és mi várható októberig az önkormányzatokban? 52:00 Búcsú

Hétvégi podcastunk, az Elvitelre legfrissebb adásában megnéztük, kikkel haverkodik Magyar Péter és Orbán Viktor az új Európai Parlamentben. Iratkozz fel a hvg360-ra, az első hónapban csupán 360 forintért!   https://hvg.hu/360/elofizetes Az e heti menü: 0:00 Intro 0:32 A Tisza Európában: a Fidesz mocskolódása célját tévesztette, Magyar Péterék élvezik az újakkal szembeni előzékenységet (Serdült Viktória) 8:23 Akikre a Fidesz büszke: az FPÖ útja a nemzetiszocialista múlttól a sörsátoron át a sporttáskában kihordott pénzig (Bábel Vilmos) Iratkozz fel a HVG Podcastokra és kapcsold be az értesítéseket, hogy egyetlen műsorunkról se maradj le!

Wojciech Przybylski talks with Hungarian journalist Viktória Serdült about PM Viktor Orbán's meetings with Vladimir Putin and Xi Jinping as well as his success in forming the Patriots for Europe group in the EU parliament.

Nagy dobra vert szövetség Brüsszelben, sunnyogás Moszkvában és Pekingben – így telt a magyar miniszterelnök első hete az EU soros elnökeként. A Patrióták Európáért valóban az Európai Parlament harmadik legnagyobb frakciója lett, a sajátos „békemisszió” mégis távolabb lökte szövetségeseitől Magyarországot. Sikerről beszélünk-e, ha összeáll egy nagy, de megkerülhető, és belülről az első perctől széthúzó frakció? Kik lesznek a Fidesz új barátai és számíthat-e arra a miniszterelnök, hogy idővel az EU-csúcsokon is bomlaszthat velük együtt? Van-e bármi ráció Orbán béketervei között, az Orosz Föderáción túl? Milyen lehet az uniós elnökség hátralévő 25 hete, ha az első ilyen volt? Ezekről kérdezte Nagy Iván László Serdült Viktóriát, a hvg.hu újságíróját és Gergely Mártont, a HVG főszerkesztőjét. Iratkozz fel a Fülke csatornájára! Spotify: tiny.cc/FulkeSpotify Apple Podcasts: tiny.cc/FulkeApple Hallgasd meg a HVG többi podcastját: Spotify: tiny.cc/HVGpodcastokSpotify Apple Podcasts: tiny.cc/HVGpodcastokApple SoundCloud: tiny.cc/HVGpodcastokSC 0:00 Intro 0:53 Mekkora siker a Fidesznek a Patrióták Európáért? 5:47 Mit lehet tudni a Patrióták tagjairól? 9:50 Hogy jönnek össze az oroszbarát és -ellenes nézetek a pártcsoportban? 12:31 Hogyan reagált a többi frakció a Patriótákra? 17:17 Tényleges szélsőjobboldali erősödés ez, vagy a számkivetettek klubja? 21:39 Hogyan lehet értelmezni Orbán moszkvai és pekingi látogatását a kijevi után? 29:33 Miért maradt el a német-magyar külügyi találkozó? 33:06 Mennyire szólhat a soros elnökség Orbánról?

Hétvégi podcastunk, az Elvitelre legfrissebb adásában a repülési káoszt, a budapesti pénzügyi káoszt, és a politikusi partikáoszt járjuk körül. Iratkozz fel a hvg360-ra, az első hónapban csupán 360 forintért! https://hvg.hu/360/elofizetes Az e heti menü: 0:00 Intro 0:32 Serdült Viktória, Imre Réka: Káosz a légi közlekedésben: nincs más megoldás, csak felkészülni rá 8:37 Szabó Yvette: Fojtogató szeretet 14:41 Parászka Boróka: Szabad a tánc? Iratkozz fel a HVG Podcastokra és kapcsold be az értesítéseket, hogy egyetlen műsorunkról se maradj le!Iratkozz fel a HVG Podcastokra és kapcsold be az értesítéseket, hogy egyetlen műsorunkról se maradj le!

El audio incluido corresponde a las noticias del miércoles 3 de julio.

Hay una guerra cultural contra los hombres, una guerra que busca hacer que los hombres sean débiles y menos masculinos. ¿Cómo deberían reaccionar los cristianos ante este asalto? ¿Estamos llamados a debilitarnos y quedarnos al margen o estamos llamados a la acción para proceder y defender a nuestras familias y a nuestra nación? Hablemos de ello. HECHOS 16:6-25 --- Send in a voice message: https://podcasters.spotify.com/pod/show/amado/message

In this episode, Manali Bhave, MD; Annalise Labatut, PharmD, BCOP; and nurse practitioner Jamie L. Carroll, CNP, APRN, MSN, begin by discussing the landmark EMERALD study that led to FDA approval of elacestrant, the first oral selective estrogen receptor degrader (SERD) for treatment of hormone receptor–positive/HER2-negative metastatic breast cancer. Dr. Bhave also briefly reviews ongoing clinical trials of other oral SERDs for estrogen receptor–positive/HER2-negative metastatic breast cancer. Next, the panel discusses the possible adverse effects with elacestrant, potential drug–drug interactions, and their personal experiences with managing adverse effects in their patients. Finally, the discussion turns to methods for promoting treatment adherence and persistence and briefly touches on insurance coverage and affordability, including ways that patients and providers can work together to ensure access to approved oral SERDs.Presenters:Manali Bhave, MDPhase I Medical DirectorAssistant ProfessorDepartment of Hematology & Medical OncologyWinship Cancer InstituteEmory UniversityAtlanta, GeorgiaAnnalise Labatut, PharmD, BCOPOncology Clinical Pharmacy Specialist – Breast OncologyEmory Healthcare/Winship Cancer InstituteAtlanta, GeorgiaJamie L. Carroll, CNP, APRN, MSNAssistant Professor of Medical OncologyMayo ClinicRochester, MinnesotaLink to the full program:https://bit.ly/3UT5Be8Claim CME Credit:https://bit.ly/4dBuxhx 

Hungary has seen its biggest anti-government protests in years over the past couple of weeks. But just how dangerous is this moment for Viktor Orbán? This week our favourite Hungarysplainer Viktória Serdült joins us to decipher the scandal that has shaken his government. We're also talking about the legalisation of gay marriage in Greece (finally!) and a Dutch court case that could have far-reaching consequences for the war in Gaza.  FULL EPISODE TRANSCRIPT HERE: https://europeanspodcast.com/episodes/orbans-biggest-crisis Viktória is a journalist at hvg.hu. You can find her on Twitter here and her article about Hungary's EU elections can be found here in EUObserver.  This week's Inspiration Station offerings: 'Navalny' and 'Lost on Me' (Niente di vero) by Veronica Raimo. The Dutch court ruling can be found here and Euronews' piece on European military supplies to Israel can be found here. Thanks for listening! If you enjoy our podcast, we'd love it if you'd consider chipping in a few bucks a month at ⁠⁠⁠⁠⁠⁠⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠⁠⁠⁠⁠⁠⁠ (many currencies are available). You can also help new listeners find the show by ⁠⁠⁠⁠⁠⁠⁠⁠⁠leaving us a review⁠⁠⁠⁠⁠⁠⁠⁠⁠ or giving us five stars on Spotify.  00:22 Spending *most* of the week reading about Europe 02:29 Good Week: Gay marriage is now legal in Greece 07:47 Bad Week: European defence companies? 17:01 Interview: Viktória Serdült on Hungary's pardoning scandal 32:33 The Inspiration Station: 'Lost on Me' by Veronica Raimo and 'Navalny' 36:33 Happy Ending: Why kids monkey around Producers: Katy Lee and Wojciech Oleksiak Mixing and mastering: Wojciech Oleksiak Music: Jim Barne and Mariska Martina ⁠⁠⁠⁠⁠⁠⁠⁠⁠Instagram⁠⁠⁠⁠⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠⁠ ⁠⁠⁠⁠⁠Threads⁠⁠⁠⁠⁠ |⁠⁠⁠⁠⁠⁠⁠ ⁠⁠Twitter⁠⁠⁠⁠⁠⁠⁠⁠⁠ | ⁠Mastodon⁠ | ⁠⁠⁠⁠⁠⁠⁠⁠hello@europeanspodcast.com⁠

En 'Más de uno' hablamos de las personas altamente sensibles, un rasgo de la personalidad que condiciona la vida de muchas personas que tienen una gran empatía, creatividad, emocionalidad, pensamiento profundo y analítico. 

In Part 1, you learned how illiberal regimes have used the political tools at their disposal – and their rich friends – to turn the media outlets of democratic European countries into propaganda machines. In Part 2 we're exploring the legal tools needed to complete the job and talking to local journalists who found themselves on the receiving end of these takeovers. Finally, we're asking: how can you stop a wannabe autocrat doing this in *your* country?  This series was funded by Journalism Fund Europe, the Allianz Foundation, and supporters of The Europeans. Thanks for listening. If you enjoy our podcast and would like to help us keep making it, we'd love it if you'd consider chipping in a few bucks a month at ⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠ (many currencies are available). You can also help new listeners find the show by ⁠⁠⁠leaving us a review⁠⁠⁠ or giving us five stars on Spotify.  Credits Reporters: Viktória Serdült, Dimitar Ganev and Wojciech Oleksiak Writers: Wojciech Oleksiak and Dimitar Ganev Production, scoring, sound design and mixing: Wojciech Oleksiak Editors: Adam Zulawski and Katy Lee Editorial support: Katz Laszlo and Dominic Kraemer Director of recording sessions: Dominic Kraemer  Artwork: RTiiiKA Thanks for talking to us: Vesislava Antonova, Ervin Gűth, Antal Józing, Zuzanna Nowicka, Venelina Popova, Anna Wójcik, Spas Spassov, Marek Twaróg, Ágnes Urbán, and Cezary Węgliński.⁠⁠Instagram⁠⁠ | Bluesky | ⁠⁠Twitter | hello@europeanspodcast.com

It's a playbook that's been used by illiberal governments across Central and Eastern Europe: muzzling the media until it resembles little more than propaganda. But how exactly does one go about dismantling the free press, in a democratic country within the European Union?  In Part 1 of this two-part special, Viktória Serdült, Dimitar Ganev and our producer Wojciech Oleksiak ask: how the hell did we get here? And how did the local press become such a powerful political weapon? This series was funded by Journalism Fund Europe, the Allianz Foundation, and supporters of The Europeans. Thanks for listening. If you enjoy our podcast and would like to help us keep making it, we'd love it if you'd consider chipping in a few bucks a month at ⁠⁠⁠patreon.com/europeanspodcast⁠⁠⁠ (many currencies are available). You can also help new listeners find the show by ⁠⁠⁠leaving us a review⁠⁠⁠ or giving us five stars on Spotify.  Credits Reporters: Viktória Serdült, Dimitar Ganev and Wojciech Oleksiak Writers: Wojciech Oleksiak and Dimitar Ganev Production, scoring, sound design and mixing: Wojciech Oleksiak Editors: Adam Zulawski and Katy Lee Editorial support: Katz Laszlo and Dominic Kraemer Director of recording sessions: Dominic Kraemer  Artwork: RTiiiKA Thanks for talking to us: Vesislava Antonova, Ervin Gűth, Antal Józing, Zuzanna Nowicka, Venelina Popova, Anna Wójcik, Spas Spassov, Marek Twaróg, Ágnes Urbán, and Cezary Węgliński. ⁠⁠Instagram⁠⁠ | Bluesky | ⁠⁠Twitter | hello@europeanspodcast.com

¿Qué pasaría si la iglesia de hoy comprendiera firmemente la realidad de que hay que ser débil para ser santificado?

In today's conversation, we're delving into the world of nutrition with Garret Serd, and we go on a journey through various dietary approaches. From the concept of reverse dieting to the intriguingly named Million Dollar Body Program, Nate discusses the perks and drawbacks of each nutritional framework. Ever wondered what happens when you step away from these frameworks? We're also diving into the realm of setting yourself up for nutritional success, as well as the intricacies of the Macro-Based Eating Framework for long-term triumph. But that's not all – stay tuned as Garrett chimes in on the metabolic reset vs reverse dieting debate. Is reverse dieting truly a futile effort? Join us as we unravel the mysteries of conquering cravings, balancing hunger, and restoring healthy calorie levels, all while exploring the flexible realm of calorie tracking. And let's not forget the incredible journey of Tandem, an empowering coaching ally since 2012, and Garrett's reflections on wrangling chaos amidst the bustling domains of life and business. Get ready for a riveting nutritional odyssey!   [0:00 - 9:44] Nate talks about the pros and cons of different styles of nutrition. Exploring Nutritional Frameworks: From Reverse Dieting to the Million Dollar Body Program. What happens when you stop the framework? Is it impossible to do intuitive eating when your diet includes hyper palatable foods? Setting yourself up for success with nutrition. [9:45 - 19:24] Optimizing Nutrition within the Macro-Based Eating Framework for Long-Term Success. Garrett shares his thoughts on metabolic reset vs reverse dieting. Why is reverse dieting a waste of time? What is metabolic reset and why does it matter? [19:25 - 27:07] Overcoming Cravings and Hunger to Restore Healthy Calorie Levels. Flexible calorie tracking approach. Tandem: Empowering Clients through Active Coaching since 2012. Balancing Chaos: Garrett's Struggle with Busyness in Life and Business.  

Welcome to this episode on how to change your identity around exercise. In today's conversation, I'm thrilled to welcome our special guest, Garrett Surd. We'll be exploring the transformative power of mindset and identity when it comes to achieving our fitness goals. It's not just about nutrition; it's about reshaping how we see ourselves and our relationship with exercise. We'll delve into the idea of emulating successful strategies, utilizing repetition through automation, and understanding why consistency is the key to mastery. Moreover, we'll discuss the challenges of battling societal expectations and the benefits of borrowing from others' experiences. Knowing who your role models are plays a significant role in this process, and we'll uncover the importance of finding the right inspirations for your unique journey. Get ready to unlock the secrets of transforming your exercise identity for a healthier, fitter you. Let 's dive in! [0:00 - 8:30] How to change your identity around exercise. Introduction of the episode and what to expect. Changing mindset and identity is crucial for achieving desired results, not solely dependent on nutrition. How can we emulate the results of their work? The power of repetition through automation. [8:31 - 15:50] Why consistency is the mother of mastery? Battling societal expectations of what is acceptable. Borrowing from other people. The importance of knowing who your role models are.  

Hoy reconocemos que el amor es libre y que no se trata de cambiar a las personas para que cumplan nuestras expectativas, sino de verles y amarles por quienes son.En este episodio hablamos de:El amor verdadero implica aceptar a alguien tal cual es, sin querer cambiar nada en esa personaAmar es renunciar a nuestras expectativas y permitir que la otra persona sea quien realmente esEl amor saludable se basa en la aceptación mutua y el crecimiento conjuntoSi quieres conocer más de Despertando Podcast síguenos en nuestras redes sociales:Instagram: https://www.instagram.com/despertandodurmiendo Facebook: https://www.facebook.com/despertandopodcast TikTok: https://www.tiktok.com/@despertandodurmiendo YouTube: https://www.youtube.com/c/DespertandoDurmiendoPodcastSi quieres conocer más sobre nuestros podcasts visita https://www.dudasmedia.com/Voz: Aura RamírezGuion: Alis EscobarDirección Creativa: Alis EscobarDiseño Sonoro: Alfredo CruzDiseño Gráfico: Beca SánchezÁrea Digital: Nancy EdidÁrea Digital (YouTube): Camila MorenoÁrea Digital (TikTok): Yexa Vega Hosted on Acast. See acast.com/privacy for more information.

In this episode, Garrett discusses the truth about reverse dieting and shares ways to optimize training and recovery. He emphasizes the importance of the post-dieting phase in boosting metabolism and preventing yo-yo dieting and explains his approach to fat loss and intuitive eating. The episode also explores immunity hacks and highlights the crucial role of sleep in promoting overall well-being. Overall, the episode provides valuable guidance for anyone looking to achieve long-term success in their nutrition and fitness journey.   Garrett Serd, also known as Coach G, is a registered dietitian, certified personal trainer, and certified wellness coach. His passion for nutrition and fitness began in 2004 when he battled anorexia nervosa at 16 years old. He spent every waking minute learning about nutrition, fitness, and healthy living. He earned a Bachelor of Science degree in Nutrition and Dietetics from Louisiana Tech University and a Master of Science degree in Nutrition & Exercise from the University of Nebraska-Lincoln. Garrett founded Tandem Nutrition in 2012, where he serves as a women's fat loss expert and continues to inspire and motivate individuals to lead healthier and happier lives.   Key Highlights: [00:01 - 08:31] Diet and Weight Training in Fat Loss and Metabolism ●      The purpose of weight training is to maintain or grow muscle mass. ●      Diet is the main driver for fat loss, but weight training helps maintain muscle mass, which is important for a healthy metabolism. ●      Garrette advises going to the gym with the mindset of progressively overloading muscles with challenging weights rather than trying to burn as many calories as possible. ●      Garrett explains that soreness and being out of breath are not indicators of a great workout. [08:32 - 18:52] Exploring Immunity Hacks ●      Garrett asks some questions to Nate about the aura ring, wearing socks to bed, and cold water therapy. ●      They discuss using the "Aura Ring" to track trends in their sleep, recovery, and health markers like respiratory rate and heart rate variability. ●      Nate talks about cryotherapy and cold water therapy, including their benefits for mental health and stress management. ●      Garrettes immunity hack is taking athletic greens and eating a lot of fruits and veggies to optimize nutrient intake and reduce exposure to toxins. ●      They emphasize the importance of sleep and how it helps them manage anxiety and stress. [18:53 - 20:16] 5-Step Guide for Effective Strength Training Workouts ●      Garrett has a five-step guide to help women set up strength training workouts ●      The guide breaks down the steps to create effective fat-burning and muscle-building workouts ●      The guide takes readers through the process of determining the number of sets and reps and which exercises to do, with notes on rep ranges, rest, and soreness ●      Garrett encourages people to try the guide for six weeks, even if it doesn't seem "sexy," as it's better than a boot camp. [20:17 - 26:52] Closing Segment ●      Nate throws some hard-hitting questions to Garrett: The next big thing in fitness? If you needed to make a thousand dollars as fast as possible, you would do…? The number one physical possession I own is…? If I could have one superpower, it would be…? If you could completely delete one song from existence and human memory, it would be..? The strangest thing I've ever been asked at the gym is…?     Key Quotes:   “The purpose of weight training is to maintain muscle mass, to grow muscle mass.” - Garrett Serd   “You should not leave a workout feeling annihilated. You should feel a workout feeling stimulated.” - Garrett Serd   “Soreness is not an indicator of a great workout.” - Garrett Serd   “The reason why the body fights back is, because, again, it wants to have more body fat, but when you give it ample, no calories, there's a difference in what it sees and what it gets.” - Garrett Serd     CONNECT WITH COACH G:   https://tandemnutrition.com/online-coaching/   Getnatesbook - This book is a must-have for anyone looking to drop belly fat and eliminate love handles permanently with expert tips on the 7 daily investments for health and wealth, the one type of cardio you need to include, and a handy checklist to hold yourself accountable to your goals. Don't miss out on this game-changing resource - get your copy today!      Here's how I can help you reach your goals! Get leaner. Live Longer. Be Legendary. 1. Visit N8training.com - mastermind 2. Join our 5-Day Morning Routine Challenge 3. Get my super easy and accessible FREE 5-Day Sugar Detox Program. All you have to do is put in your email and receive access together with a handbook! Thefreesugardetox.com 4.  Start by understanding the science and simplicity of carb backloading for fat loss - go to GetNatesBook.Com. to get a free copy of Nate's bestseller “The Million Dollar Body Method” 5. Get more great tips to get leaner by connecting with me on Instagram @lowcarbhustle 6. Join the MDB Mastermind for just a buck! If you want accountability, coaching, and an amazing training program to get leaner, this is what you need. Go to nate.fit to find out more and get your first 2 weeks for just 1 dollar. 7. Follow us on our Youtube channel: Youtube.com/@n8training If you liked the show, please LEAVE A 5-STAR REVIEW, and share it on social media to get reposted to over 12k of the homies.

In this episode, Garrett discusses the truth about reverse dieting and shares ways to optimize training and recovery. He emphasizes the importance of the post-dieting phase in boosting metabolism and preventing yo-yo dieting and explains his approach to fat loss and intuitive eating. The episode also explores immunity hacks and highlights the crucial role of sleep in promoting overall well-being. Overall, the episode provides valuable guidance for anyone looking to achieve long-term success in their nutrition and fitness journey.   Garrett Serd, also known as Coach G, is a registered dietitian, certified personal trainer, and certified wellness coach. His passion for nutrition and fitness began in 2004 when he battled anorexia nervosa at 16 years old. He spent every waking minute learning about nutrition, fitness, and healthy living. He earned a Bachelor of Science degree in Nutrition and Dietetics from Louisiana Tech University and a Master of Science degree in Nutrition & Exercise from the University of Nebraska-Lincoln. Garrett founded Tandem Nutrition in 2012, where he serves as a women's fat loss expert and continues to inspire and motivate individuals to lead healthier and happier lives.   Key Highlights: [00:01 - 09:16] Opening Segment ●      One of the biggest nutrition myths that drive Garrett absolutely bonkers is the belief that once you are done dieting, you are done with your fat-loss journey. ●      Garrette stresses the post-dieting phase's significance in boosting metabolism and avoiding yoyo dieting. ●      Garrett Serd recounts his experience of overcoming a decade-long eating disorder and becoming a dietician. In 2012, he founded Tandem Nutrition, where he specializes in creating fat loss strategies for women. ●      He works with women exclusively, offering specific strategies that work well for them, especially with the different age changes, menopause, and hormones. [09:17 - 16:35] Diet Phases and Maintenance ●      Four dieting phases: fat loss, metabolic reset, next phase, and intuitive eating approach. ●      Clients are guided to lose weight at a controlled rate while preserving muscle mass during a 12-16 week fat loss phase, followed by transitioning to an intuitive eating approach through a metabolic reset phase. ●      Reverse dieting can have a negative impact on an individual's health and decrease their long-term muscle gain potential. ●      Going back to the maintenance level after a diet is important because the maintenance level changes due to adaptation. ●      Increasing calories can decrease stress hormones and water retention and give more energy for physical activity. [16:36 - 25:41] Transitioning to Intuitive Eating Without Calorie Counting ●      Garrett explains maintenance phase is shorter because we tend to diet. To reset the metabolism, we need at least half the time of the previous diet. ●      Intuitive dieting aims to fit within a certain framework, but portion sizes and calorie counting are not emphasized. ●      The maintenance phase is important for the body to reset and adjust to a new calorie level, allowing hunger hormones to return to normal levels before moving into intuitive eating. ●      Garrett explains transitioning from tracking to intuitive eating involves choosing a meal or day each week not to track and build confidence in achieving results without tracking every day in four steps.   Key Quotes: “The purpose of weight training is to maintain muscle mass, to grow muscle mass.” - Garrett Serd   “You should not leave a workout feeling annihilated. You should feel a workout feeling stimulated.” - Garrett Serd   “Soreness is not an indicator of a great workout.” - Garrett Serd   “The reason why the body fights back is, because, again, it wants to have more body fat, but when you give it ample, no calories, there's a difference in what it sees and what it gets.” - Garrett Serd     CONNECT WITH COACH G:   https://tandemnutrition.com/online-coaching/   Getnatesbook - This book is a must-have for anyone looking to drop belly fat and eliminate love handles permanently with expert tips on the 7 daily investments for health and wealth, the one type of cardio you need to include, and a handy checklist to hold yourself accountable to your goals. Don't miss out on this game-changing resource - get your copy today!      Here's how I can help you reach your goals! Get leaner. Live Longer. Be Legendary. 1. Visit N8training.com - mastermind 2. Join our 5-Day Morning Routine Challenge 3. Get my super easy and accessible FREE 5-Day Sugar Detox Program. All you have to do is put in your email and receive access together with a handbook! Thefreesugardetox.com 4.  Start by understanding the science and simplicity of carb backloading for fat loss - go to GetNatesBook.Com. to get a free copy of Nate's bestseller “The Million Dollar Body Method” 5. Get more great tips to get leaner by connecting with me on Instagram @lowcarbhustle 6. Join the MDB Mastermind for just a buck! If you want accountability, coaching, and an amazing training program to get leaner, this is what you need. Go to nate.fit to find out more and get your first 2 weeks for just 1 dollar. 7. Follow us on our Youtube channel: Youtube.com/@n8training If you liked the show, please LEAVE A 5-STAR REVIEW, and share it on social media to get reposted to over 12k of the homies.